Positron emission tomography imaging in oncology

Radiologic Clinics of North America

Volumn 39, Issue 5, 2001, Pages 883-917

  Delbeke, Dominique ^b   Martin, William H ^b  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 131; ANTINEOPLASTIC AGENT; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; IODINE 131; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; PENTETREOTIDE IN 111; RADIOPHARMACEUTICAL AGENT;

BREAST CARCINOMA; CANCER DIAGNOSIS; CANCER SCINTISCANNING; COLORECTAL CARCINOMA; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; ENDOCRINE TUMOR; ESOPHAGUS CARCINOMA; HEAD AND NECK CANCER; HEPATOBILIARY SYSTEM CANCER; HUMAN; LYMPH NODE METASTASIS; LYMPHOMA; MELANOMA; MULTIMODALITY CANCER THERAPY; ONCOLOGY; PANCREAS CARCINOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REIMBURSEMENT; REVIEW; SARCOMA; STOMACH CARCINOMA; WHOLE BODY SCINTISCANNING;

EID: 0034804495     PISSN: 00338389     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0033-8389(05)70319-5     Document Type: Article

References (237)

1. Metastases in carcinoma: Analysis of 100 autopsied cases
2. Prospective comparison of 18F-FDG PET with conventional imaging modalities (CT, MRI, US) in lymph node staging of head and neck cancer
3. Grading liposarcomas with PET using [18F] FDG
4. Evaluation of breast masses and axillary lymph nodes with [F-18]2-deoxy-2-fluoro-D-glucose PET
5. Axillary lymph node metastases: Screening with [F-18]2-deoxy-2-fluoro-D-glucose (FDG) PET
6. Monitoring liver tumor therapy with [18F]FDG positron emission tomography
7. Positron emission tomography in the clinical staging of patients with stage I and II testicular germ cell tumors
8. Comparative diagnostic accuracy of magnetic resonance imaging and immunoscintigraphy for detection of bone marrow involvement in patients with malignant lymphoma
9. Image fusion using POACS for MRI, CT, and PET images
10. Recurrence of head and neck cancer after surgery or irradiation: Prospective comparison of 2-deoxy-2[F-18]fluoro-D-glucose PET and MR imaging diagnoses
11. Drug theapy: Treatment of non Hodgkin's lymphoma
12. Metastatic head and neck cancer: Role and usefulness of FDG PET in locating occult primary tumors
13. Assessment of axillary lymph node involvement in breast cancer patients with positron emission tomography using radiolabeled 2-(fluorine-18)-fluoro-2-deoxy-D-glucose
14. Metabolic characterization of breast tumors with positron emission tomography using F-18 fluorodeoxyglucose
15. Utility of PET in breast cancer
16. Positron emission tomography in the diagnosis of renal cell carcinoma
17. Positron emission tomography: A new, precise imaging modality for detection of primary head and neck tumors and assessment of cervical adenopathy
18. Benign causes of 18-FDG uptake on whole body imaging
19. Wholebody 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography (FDG PET) for accurate staging of Hodgkin's disease
20. F-18-fluorodeoxyglucose PET in vivo evaluation of pancreatic glucose metabolism for detection of pancreatic cancer
21. Pancreatic cancer detected by positron emission tomography with 18F-labelled deoxyglucose: Method and first results
22. Evaluation of preoperative chemotherapy using PET with fluorine-18-fluorodeoxyglucose in breast cancer
23. Clinical value of whole-body positron emission tomography with [18F]fluorodeoxyglucose in recurrent colorectal cancer
24. The role of FDG PET in the preoperative assessment of N-staging in head and neck cancer
25. 18fluorodeoxyglucose positron emission tomography in the staging of recurrent breast carcinoma
26. Possible role of FDG PET in the evaluation of urologic malignancies
27. Pilot study of positron emission tomography in patients with advanced head and neck cancer receiving radiotherapy and chemotherapy
28. A combined PET/CT scanner for clinical oncology
29. Positron emission tomography and ultrasonography. A comparative retrospective study assessing the diagnostic validity in lymph node metastases of malignant melanoma
30. Improvement in staging of esophageal cancer with the addition of positron emission tomography
31. Determination of malignancy of thyroid nodules with positron emission tomography
32. Indium-11 OncoScint CR/OV and F-18 FDG in colorectal and ovarian carcinoma recurrences: Early observations
33. FDG PET detection of unknown primary tumors
34. Indeterminate adrenal mass in patients with cancer: Evaluation at PET with 2-[F-18]-fluoro-2-deoxy-D-glucose
35. Staging of metastatic melanoma by whole-body positron emission tomography using 2-fluorine-18-fluoro-2-deoxy-D-glucose
36. Detection of lymph nodes metastases of squamous-cell cancer of the head and neck with FDG PET and MRI
37. Thickness, cross sectional areas and depth of invasion in the prognosis of cutaneous melanoma
38. Early prediction of treatment outcome in head and neck cancer with 2- 18FDG PET
39. Fluorine-18 deoxyglucose positron emission tomography for the detection of bone metastases in patients with non-small cell lung cancer
40. Detection of lymphoma in bone marrow by whole-body positron emission tomography
41. Experience with positron emission tomography (PET) scans in patients with ovarian cancer
42. Pancreatic adenocarcinoma: Combination of MR angiography and MR cholangiopancreatography for the diagnosis and assessment of resectability
43. Positron emission tomography with fluorodeoxyglucose to evaluate tumor response and control after radiation therapy
44. The clinical utility of endoscopic ultrasound-guided fine-needle aspiration in the diagnosis and staging of pancreatic carcinoma
45. Nuclear medicine in head and neck oncology: Reality and perspectives
46. The histogenesis and biologic behavior of primary human malignant melanoma of the skin
47. PET in lung cancer
48. The role of positron emission tomography in the management of bone metastases
49. Normal physiological and benign pathological variants of 18-fluoro-2-deoxyglucose positron emission tomography scanning: Potential for error in interpretation
50. Detection of bone metastases in breast cancer with FDG PET: Differing metabolic activity in osteoblastic and osteolytic lesions
51. Detection of response to chemotherapy using positron emission tomography in patients with oesophageal and gastric cancer
52. FDG PET for detection and therapy control of metastatic germ cell cancer
53. Prospective evaluation of fluorine-18-FDG PET in presurgical staging of the axilla in breast cancer
54. Association between [18F]fluorodeoxyglucose uptake and post-operative histopathology, hormone receptor status, thymidine labelling index and p53 in primary breast cancer: A preliminary observation
55. FDG PET and CT in evaluation of chemotherapy in advanced head and neck cancer
56. Positron emission tomography in the detection and management of metastatic melanoma
57. Positron tomographic assessment of estrogen receptors in breast cancer: Comparison with FDG PET and in vitro receptor assays
58. Benign versus malignant intraosseous lesions: Discrimination by means of PET with 2-[F18] fluoro-2-deoxy-D-glucose
59. Oncological applications of FDG PET imaging: Brain tumors, colorectal cancer, lymphoma and melanoma
60. Oncological applications of FDG PET imaging
61. 18F-fluorodeoxyglucose imaging with positron emission tomography in the follow-up of patients with lymphoma
62. 18F-fluorodeoxyglucose imaging with positron emission tomography for initial staging of Hodgkin's disease and lymphoma
63. Value of iterative reconstruction, attenuation correction, and image fusion for interpretation of FDG images using an integrated dual-head coincidence camera with X-ray based attenuation maps in patients with known or suspected malignancy
64. Evaluation of benign vs. malignant hepatic lesions with positron emission tomography
65. Optimal interpretation of F-18FDG imaging of FDG PET in the diagnosis, staging and management of pancreatic carcinoma
66. The role of hybrid cameras in oncology
67. Staging recurrent metastatic colorectal carcinoma with PET
68. Whole-body positron emission tomography (PET) for diagnosis of residual mass in patients with lymphoma
69. FDG PET: Elevated plasma glucose reduces both uptake and detection rate of pancreatic malignancies
70. Fluorine-18 fluorodeoxyglucose positron emission tomography and iodine-131 whole body scintigraphy in the follow-up of differentiated thyroid cancer
71. Follow-up of differentiated thyroid cancer: What is the value of FDG and sestamibi in the diagnostic algorithm?
72. Quantitative [F-18]fluorodeoxyglucose positron emission tomography in pretreatment and grading of sarcoma
73. Metabolic imaging of untreated prostate cancer by positron emission tomography with 18flourine-labeled deoxy-glucose
74. Whole body PET: Physiological and artifactual fluorodeoxyglucose accumulations
75. 18F-fluorodeoxyglucose positron emission tomography
76. Positron emission tomography for preoperative staging of colorectal carcinoma
77. Detection of recurrent head and neck squamous cell carcinoma after radiation therapy with 2-18F-fluoro-2-deoxy-D-glucose
78. Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: Correlation with tumor response to fluorouracil
79. Utility of FDG PET for investigating unexplained plasma CEA elevation in patients with colorectal cancer
80. 18F-fluorodeoxyglucose positron emission tomography
81. Elevated levels of glucose transport and transporter messenger RNA are induced by rats or src oncogenes
82. Diagnosis of pancreatic cancer by 2[F-18]-fluoro-2-deoxy-D-glucose positron emission tomography
83. FDG PET in the detection of pancreatic cancer liver metastases
84. Metabolic trapping as a principle of radiopharmaceutical design: Some factors responsible for the biodistribution of [18F]2-deoxy-2-fluoro-D-glucose
85. Cost effective analysis modeling of the role of FDG PET in the management of patients with recurrent colorectal cancer
86. Potential role of fluorine-18-deoxyglucose (FDG) positron emission tomography (PET) in the staging of primitive and recurrent medullary thyroid carcinoma
87. Occult primary tumors of the head and neck: Lack of benefit from positron emission tomography imaging with 2-[F-18]fluoro-2-deoxy-D-glucose
88. Distinguishing tumor recurrence from irradiation sequelae with positron emission tomography in patients with advanced head and neck cancer receiving radiotherapy and chemotherapy
89. Positron emission tomography of patients with head and neck carcinoma before and after high dose irradiation
90. PET evaluation of soft-tissue masses with fluorine-18 fluoro-2-deoxy-D-glucose
91. Initial assessment of positron emission tomography using 2-fluoro-18-fluoro-2-deoxy-D-glucose in the imaging of malignant melanoma
92. Comparison of 18-FDG PET with 131-iodine and 99mTc-sestamibi scintigraphy in differentiated thyroid cancer
93. Fluorine-18 fluorodeoxyglucose positron emission tomography in the follow-up of differentiated thyroid cancer
94. Chronic osteomyelitis: Detection with FDG PET and correlation with histopathologic findings
95. Pre-operative staging of colorectal carcinoma using positron emission tomography
96. Fluorodeoxyglucose imaging of advanced head and neck cancer after chemotherapy
97. Glucose uptake, perfusion, and cell proliferation in head and neck tumors: Relation of positron emission tomography to flow cytometry
98. Uptake of 2-deoxy, 2-(18F) fluoro-D-glucose in bladder cancer: Animal localization and initial patient positron emission tomography
99. Endoscopic ultrasonography of the pancreas
100. Characterization of adrenal masses using MR imaging with histopathologic correlation
101. FDG PET evaluation of indeterminate pancreatic masses
102. Fluorine-18fluorodeoxyglucose positron emission tomography is useless for the detection of local recurrence after radical prostatectomy
103. Interindividual variance of glucose-6-phosphatase (G-6-Pse) expression in renal cell cancer
104. Whole body FDG PET imaging for staging of Hodgkin's disease and lymphoma
105. Positron emission tomography in urological oncology
106. Cancer detection with whole-body PET using [F-18]fluoro-2-deoxy-D-glucose
107. Effectiveness of positron emission tomography for the detection of melanoma metastases
108. Assessment of primary and metastatic ovarian cancer by positron emission tomography (PET) using 2-[18FDG]deoxy-glucose (2-[18F]FDG)
109. Clinical utility of FDG PET in detecting head and neck tumors: A comparison of diagnostic methods and modalities
110. Evaluation of pancreatic tumors with positron emission tomography and F-18 fluorodeoxyglucose: Comparison with CT and US
111. Recurrent rectal cancer and scar: Differentiation with PET and MR imaging
112. Extracranial head and neck: PET imaging with 2-[F-18]fluoro-2-deoxy-d-glucose and MR imaging correlation
113. False-negative fluorine-18-FDG PET in metastatic carcinoid
114. Positron emission tomography studies in patients with locally advanced and/or metastatic breast cancer: A method for early therapy evaluation?
115. Persistent tumor 18f-fdg uptake after a few cycles of polychemotherapy is predictive of treatment failure in non-Hodgkin's lymphoma
116. Imaging of metastases of thyroid carcinoma with fluorine- 18 fluorodeoxyglucose
117. 18F-fluorodeoxyglucose imaging in preoperative diagnosis of thyroid malignancy
118. Monitoring of neoadjuvant therapy response of soft-tissue and musculoskeletal sarcoma using fluorine-18-FDG PET
119. Prognostic factors in Hodgkin's disease: Implications for modern treatment
120. Value of bilateral bone marrow biopsy specimens in non-Hodgkin's lymphoma
121. Comparison and discrepancy of 18F-2-deoxyglucose positron emission tomography and Tc- 99m MDP bone scan to detect bone metastases
122. Fluorodeoxyglucose positron emission tomography in pancreatic cancer: An unsolved problem
123. Detection of cholangiocarcinoma in primary sclerosing cholangitis by positron emission tomography
124. Metabolic imaging of human extremity musculoskeletal tumors by PET
125. FDG PET in head and neck cancer
126. Differentiation of residual or recurrent tumors from post-treatment changes with F- 18 FDG PET
127. FDG PET to evaluate combined intra-arterial chemotherapy and radiotherapy of head and neck neoplasms
128. Hexokinase, differentiation, and growth rates of transplanted tumors
129. Fluorine-18-fluorodeoxyglucose assessment of glucose metabolism in bone tumors
130. Detection of unknown occult primary tumors using positron emission tomography
131. Detection of local recurrence of soft-tissue sarcoma with positron emission tomography using [18F] fluorodeoxyglucose
132. Imaging of breast cancer with [18F]fluorodeoxyglucose and positron emission tomography
133. The role of whole-body positron emission tomography with [18F]fluorodeoxyglucose in identifying operable colorectal cancer
134. Routine bone scintigraphy is of limited value in the clinical assessment of untreated patients with Hodgkin's disease
135. Head and neck cancer: Detection of recurrence with PET and 2-[F-18]fluoro-2-deoxy-D-glucose
136. Increased glucose metabolism in untreated non Hodgkin's lymphoma: A study with positron emission tomography and fluorine- 18 fluorodeoxyglucose
137. Comparison of fluorine-18-fluorodeoxyglucose PET, MRI and endoscopy for staging head and neck squamous-cell carcinomas
138. Uptake of carbon-11 methionine and fluorodeoxyglucose in non-Hodgkin's lymphoma: A PET study
139. The designimplementation of COSEM an iterative algorithm for a fully 3D list mode data
140. Influence of the blood glucose concentration on FDG uptake in cancer: A PET study
141. Surveillance for recurrent head and neck cancer using positron emission tomography
142. Evaluation of chemotherapy response in patients with advanced head and neck cancer using [F-18]fluorodeoxyglucose positron emission tomography
143. Role of positron emission tomography in staging esophageal cancer
144. Prospective evaluation of 2-[18F]-2-deoxy-D-glucose positron emission tomography in staging of regional lymph nodes in patients with cutaneous malignant melanoma
145. FDG PET in the prediction of survival of patients with cancer of the pancreas: A pilot study
146. Positron emission tomography using [(18)F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy
147. A comparative diagnostic study of head and neck nodal metastases using positron emission tomography
148. Pancreatic adenocarcinoma: CT versus MR imaging in the evaluation of resectability-report of the Radiology Diagnostic Oncology Group
149. Quantification of glucose utilization in liver metastases: Parametric imaging of FDG uptake with PET
150. Chemotherapy for nonmetastatic osteogenic sarcoma: The Memorial Sloan-Kettering experience
151. Fluorodeoxyglucose imaging: A method to assess the proliferative activity in human cancer in vivo-comparison with DNA flow cytometry in head and neck tumors
152. Prediction of survival with fluorine-18-fluoro-deoxyglucose and PET in head and neck cancer
153. Evaluation of treatment response to radiotherapy in head and neck cancer with fluorine-18 fluorodeoxyglucose
154. Physiochemical properties and isoenzyme composition of hexokinase from normal and malignant human tissues
155. Evaluation of FDG uptake by renal malignancies (primary tumor or metastases) using a coincidence detection gamma camera
156. Extranodal malignant lymphoma: Detection with FDG PET versus CT
157. Lymphoma: Role of whole-body 2-deoxy-2-[F18]fluoro D-glucose (FDG) PET in nodal staging
158. 18-F fluorodeoxyglucose-positron emission tomography as a new approach to detect lymphomatous bone marrow
159. Accuracy of whole-body fluorine-18-FDG PET for the detection of recurrent or metastatic breast carcinoma
160. Technical details of intraoperative lymphatic mapping for early stage melanoma
161. Occult primary tumors of the head and neck: Detection with 2-[F-18] fluoro-2-deoxy-D-glucose SPECT
162. Positron emission tomography in the evaluation of the negative neck in patients with oral cavity cancer
163. Positron emission tomography in the evaluation of the NO neck
164. Positron emission tomography with fluorine-18-deoxyglucose in the detection and staging of breast cancer
165. Fluorine-18-fluorodeoxyglucose PET imaging of soft-tissue sarcoma
166. Diagnostic value of positron emission tomography for detecting breast cancer
167. Detection of recurrent and metastatic colorectal cancer: Comparison of positron emission tomography and computed tomography
168. Positron emission tomography using fluorine-18 fluorodeoxyglucose in malignant lymphoma: A comparison with proliferative activity
169. Evaluation of liver tumors using fluorine-18-fluorodeoxyglucose PET: Characterization of tumor and assessment of effect of treatment
170. Comparison of fluorine-18-fluorodeoxyglucose positron emission tomography and technetium- 99m methoxyisobutylisonitrile scintimammography in the detection of breast tumors
171. Image fusion using an integrated, dual-head coincidence camera with x-ray tube-based attenuation maps
172. Relationship of chemotherapy-induced necrosis and surgical margins to local recurrence in osteosarcoma
173. Is computed tomography guided biopsy still necessary for the diagnosis of adrenal masses in patients with resectable non-small-cell lung cancer
174. Can positron emission tomography (PET) be used to detect subclinical response to cancer therapy?
175. Change induced by radiation therapy in FDG uptake in normal and malignant structures of the head and neck: Quantitation with PET
176. Use of positron emission tomography with fluorodeoxyglucose in patients with extracranial head and neck cancers
177. FDG PET evaluation of retroperitoneal metastases of testicular cancer before and after chemotherapy
178. Oncological applications of positron emission tomography with fluorine- 18fluorodeoxyglucose
179. Primary staging and follow-up of high risk melanoma patients with whole-body 18F-fluorodeoxyglucose positron emission tomography: Results of a prospective study of 100 patients
180. Predicting malignancy grade with PET in non-Hodgkin's lymphoma
181. Positron emission tomography in non-Hodgkin's lymphoma: Assessment of chemotherapy with fluorodeoxyglucose
182. 18Fluorodeoxyglucose-positron emission tomography (18FDG-PET) in the management of patients with suspected pancreatic cancer
183. Fluorodeoxyglucose whole-body positron emission tomography in colorectal cancer patients studied in routine daily practice
184. An evaluation of FDG PET in the detection and differentiation of thyroid tumors
185. Positron emission tomography using [(18)F]fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer
186. Qualitative [18F]FDG positron emission tomography in primary breast cancer: Clinical relevance and practicability
187. Contribution of PET in the diagnosis of recurrent colorectal cancer: Comparison with conventional imaging
188. Fluorodeoxyglucose positron emission tomography of soft tissue tumours: Is a non-invasive determination of biological activity possible?
189. Evaluation of neoadjuvant therapy response of osteogenic sarcoma using FDG PET
190. Cervical lymph node metastasis of thyroid papillary carcinoma imaged with fluorine-18-FDG, technetium-99m-pertechnetate and iodine-131-sodium iodide
191. Comparison of helical computerized tomography, positron emission tomography and monoclonal antibody scans for the evaluation of lymph node metastases in patients with prostate specific antigen relapse after treatment for localized prostate cancer
192. The impact of FDG positron emission tomography imaging on the management of lymphomas
193. Focal fluorine-18-fluorodeoxyglucose accumulation in inflammatory pancreatic disease
194. Metastatic prostate cancer: Initial findings of PET with 2-deoxy-2-[F18]fluoro-D-glucose
195. Neuroblastoma: Positron emission tomography with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose compared with metaiodobenzylguanidine scintigraphy
196. Pheochromocytomas that do not accumulate netaiodobenzylguanidine: Localization with PET and administration of FDG
197. Uptake of FDG by thyroid cancer: Implications for diagnosis and therapy
198. Integration of PET in radiation medicine
199. Staging of the axilla in breast cancer: An accurate in vivo assessment using positron emission tomography with 2-(fluorine-18)-fluoro-2-deoxy-D-glucose
200. A fluorinated glucose analog, 2-fluoro-2-deoxy-2-D-glucose [18F]: Nontoxic tracer for rapid tumor detection
201. Malignant melanoma: Staging with whole-body positron emission tomography and 2-[F-18]-fluoro-2-deoxy-D-glucose
202. Planar coincidence scintigraphy and PET in staging malignant melanoma
203. Positron emission tomography evaluation of residual radiographic abnormalities in postchemotherapy germ cell tumor patients
204. 2-(Fluorine-18)-fluoro-2-deoxy-D-glucose PET in detection of pancreatic cancer: Value of quantitative image interpretation
205. CT and pathologic predictive features of residual mass histologic findings after chemotherapy for nonseminomatous germ cell tumors: Can residual malignancy or teratoma be excluded?
206. Recurrence of colorectal tumors: PET evaluation
207. Wholebody positron emission tomography using fluorodeoxyglucose for staging of lymphoma: Effectiveness and comparison with computed tomography
208. Preclinical and clinical studies of bone marrow uptake of fluorine-1-fluorodeoxyglucose with or without granulocyte colony-stimulating factor during chemotherapy
209. Germ cell tumor: Differentiation of viable tumor, mature teratoma, and necrotic tissue with FDG PET and kinetic modeling
210. In vivo assessment of glucose metabolism in hepatocellular carcinoma with FDG PET
211. Value of fluorine-18-FDG PET to monitor hepatocellular carcinoma after interventional therapy
212. The application of positron emission tomographic imaging with fluorodeoxyglucose to the evaluation of breast disease
213. 18F-FDG PET in primary and metastatic thyroid cancer
214. Fluorine-18-fluorodeoxyglucose PET versus thallium- 201 scintigraphy evaluation of thyroid tumors
215. Prospective evaluation of fluorine- 18 fluorodeoxyglucose positron emission tomography in breast cancer for staging of the axilla related to surgery and immunocytochemistry
216. Whole-body PET imaging with F-18-fluorodeoxyglucose in management of recurrent colorectal cancer
217. Cost-effectiveness of whole-body FDG PET imaging in metastatic melanoma
218. FDG PET to evaluate response to hyperthermic isolated limb perfusion for locally advanced soft-tissue sarcoma
219. Positron emission tomography with F-18-fluorodeoxyglucose to evaluate the results of hepatic chemoembolization
220. Positron emission tomography to stage metastatic colorectal carcinoma to the liver
221. Prediction of surgical resectability in patients with hepatic colorectal metastases
222. Initial assessment of positron emission tomography for detection of nonpalpable regional lymphatic metastases in melanoma
223. To AC or not to AC: That is the question
224. Primary and metastatic breast carcinoma: Initial clinical evaluation with PET with the radiolabeled glucose analog 2-[F-18]-fluorodeoxy-2-D-glucose (FDG)
225. Imaging of renal cancer using positron emission tomography with 2-deoxy-2-(18F)-fluoro-D-glucose: Pilot animal and human studies
226. Detection of breast cancer in women after augmentation mammoplasty using fluorine-18-fluorodeoxyglucose-PET
227. Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: Initial evaluation
228. 131I whole body scans and elevated serum thyroglobulin levels
229. Glucose-6-phosphatase activity in normal, precancerous, and neoplastic tissues
230. Comparative biochemistry of hepatomas. III. Carbohydrate enzymes in liver tumors of different growth rates
231. Prognostic significance of axillary nodal status in primary breast cancer in relation to the number of resected nodes
232. 18FDG positron emission tomography: Prospects for detection and management
233. A prospective study of PET-FDG imaging for the assessment of head and neck squamous cell carcinoma
234. Twenty percent of bony metastases of hormone resistant prostate cancer are detected by PET-FDG whole body scanning
235. Accuracy of FDG PET in gastric cancer: Preliminary experience
236. 18F]fluoro-D-glucose in liver metastases from colon carcinoma
237. Fluorine-18 fluorodeoxyglucose positron emission tomography in the differential diagnosis of pancreatic carcinoma: A report of 106 cases